UMN Pharma, Inc.

While preparing to submit the highly anticipated Phase III results for it oral COVID-19 antiviral Xocova (ensitrelvir; S-217622), Shionogi & Co. Ltd. is facing a struggle to line up other candidates

The Japanese government has started a new funding project for pharma bioventures in the country with a new JPY50bn ($420m) budget, aiming to strengthen the domestic ecosystem for drug and vaccine deve

Shionogi & Co. Ltd. has announced progress in a Phase III trial for S-268019, its recombinant protein vaccine for COVID-19, and has also filed for the conditional rapid approval in Japan of S-217622,

Japan has one of the largest single-country pharma markets in the world, a handful of major R&D-based companies with multiple innovative drugs sold around the globe, and a record of innovation that st